Curative Biotechnology Inc (CUBT)

[My911Voice]

I go back to the audit, directors, intent to uplist and the conclusion I come to (assuming things are on the up and up) is that the reverse split will be needed to meet share price requirements for uplisting. Once there, they can get into serious discussions with big pharma. Without the RS they would have to spend a ton of money and energy to get the price meeting standards for Nasdaq.

Or we just got royally screwed which feels more like the right conclusion.